NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

Stock Information for NRX Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.